Inozyme Pharma, Inc. (INZY)
- Previous Close
5.06 - Open
5.16 - Bid 5.14 x 200
- Ask 5.20 x 100
- Day's Range
5.10 - 5.24 - 52 Week Range
2.69 - 7.80 - Volume
165,130 - Avg. Volume
261,506 - Market Cap (intraday)
346.901M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.44 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
www.inozyme.comRecent News: INZY
View More
Performance Overview: INZY
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INZY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INZY
View MoreValuation Measures
Market Cap
346.90M
Enterprise Value
249.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.87%
Return on Equity (ttm)
-88.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-88.56M
Diluted EPS (ttm)
-1.44
Balance Sheet and Cash Flow
Total Cash (mrq)
144.52M
Total Debt/Equity (mrq)
49.47%
Levered Free Cash Flow (ttm)
-55.05M
Research Analysis: INZY
View MoreCompany Insights: INZY
INZY does not have Company Insights